Observational study on the Sequent Please Neo balloon catheter for heart disease

Sequent Please Neo Extended Post-Market Clinical Follow-up Study

Fundación EPIC · NCT05788432

This study is testing how safe and effective the Sequent Please Neo balloon catheter is for people with coronary artery disease and ischemic heart disease in real-life situations.

Quick facts

Study typeObservational
Enrollment2028 (estimated)
Ages18 Years and up
SexAll
SponsorFundación EPIC (other)
Locations27 sites (Alava and 26 other locations)
Trial IDNCT05788432 on ClinicalTrials.gov

What this trial studies

This multicenter, prospective, non-randomized observational study aims to confirm the clinical safety and performance of the Sequent Please Neo balloon catheter in patients with coronary artery disease and ischemic heart disease. It will involve consecutive patients treated with this device in real-world clinical settings, adhering to the manufacturer's instructions. The study is designed to meet EU Medical Device Regulation requirements for post-market clinical follow-up, ensuring that the device's effectiveness and safety are evaluated in a diverse patient population.

Who should consider this trial

Good fit: Ideal candidates for this study are patients with coronary artery disease who are treated with the Sequent Please Neo catheter and can provide informed consent.

Not a fit: Patients with a life expectancy of less than 12 months or contraindications for antiplatelet therapy may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable data supporting the safety and effectiveness of the Sequent Please Neo catheter, potentially improving treatment options for patients with coronary artery disease.

How similar studies have performed: Other studies involving post-market clinical follow-up of medical devices have shown success in confirming safety and efficacy, making this approach a continuation of established practices.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients treated with Sequent please neo according to routine hospital practice and following instruction for use.
* Informed Consent Signed.

Exclusion Criteria:

* Patient life expectancy less than 12 months.
* Contraindication for antiplatelet therapy.
* Not meet inclusion criteria.

Where this trial is running

Alava and 26 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Coronary Artery Disease, Ischemic Heart Disease, MDR, PMCF, Paclitaxel eluting coronary balloon dilatation catheter

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.